Literature DB >> 1695649

Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.

P B Chapman1, H Yuasa, A N Houghton.   

Abstract

R24, a mouse IgG3 mAb against GD3 ganglioside, was shown to bind to itself in a homophilic manner. This was demonstrated by augmented binding of 125I-labeled R24 to the cell surface of GD3+ cells by unlabeled R24 and by direct binding of biotinylated R24 to R24 adsorbed on solid phase. Although homophilic binding was evident when R24 was bound to solid phase, R24-R24 aggregates could not be detected in solution under otherwise identical conditions. R24 bound to four other mAb (two IgG3, one IgG2a, one IgM) directed against GD3 but did not bind to a panel of 21 other mAb including other IgG3 mAb and mAb directed against non-GD3 ganglioside. Evidence implicating the GD3-binding site of R24 in homophilic binding included the following observations: 1) F(ab')2 fragments of R24 could bind to R24, 2) an antiidiotypic mAb against the GD3-binding site of R24 inhibited R24 homophilic binding, 3) an IgM anti-GD3 mAb also demonstrated homophilic binding to R24, and 4) homophilic binding was a function of immunoreactivity and avidity for GD3. R24 variants with 40-fold lower avidity for GD3 demonstrated a similar decrease in homophilic binding. Inasmuch as R24 bound to R24 F(ab')2 fragments and specifically to anti-GD3 mAb, it appeared that the target for homophilic binding was an epitope within the V region of anti-GD3 mAb. It is likely that homophilic interactions result in increased affinity of R24 for GD3 through increased effective valency of antibody-Ag complexes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695649

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction.

Authors:  N S Greenspan; L J Cooper
Journal:  Springer Semin Immunopathol       Date:  1993

2.  GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes.

Authors:  E B Reilly; G Antognetti
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

4.  Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Authors:  S Ohta; A Honda; Y Tokutake; H Yoshida; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Authors:  Chun-Yen Tsao; Francesco Sabbatino; Nai-Kong V Cheung; Jeff Chi-Feng Hsu; Vincenzo Villani; Xinhui Wang; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

6.  Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Authors:  P B Chapman; S D Gillies; A N Houghton; R M Reilly
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

7.  Engineered humanized dimeric forms of IgG are more effective antibodies.

Authors:  P C Caron; W Laird; M S Co; N M Avdalovic; C Queen; D A Scheinberg
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

8.  Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.

Authors:  Beatrix Kotlan; Szabolcs Horvath; Klara Eles; Vanda K Plotar; Gyorgy Naszados; Katalin Czirbesz; Miri Blank; Emil Farkas; Laszlo Toth; Jozsef Tovari; Andras Szekacs; Yehuda Shoenfeld; Maria Godeny; Miklos Kasler; Gabriella Liszkay
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.